Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News

23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.

23 equities research analysts have issued 12-month target prices for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $625.00 to $1,050.00. On average, they anticipate the company's stock price to reach $854.13 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.

Regeneron Pharmaceuticals' stock was trading at $721.49 at the beginning of the year. Since then, REGN shares have increased by 2.4% and is now trading at $738.46.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our REGN earnings forecast.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its earnings results on Friday, February, 3rd. The biopharmaceutical company reported $12.56 EPS for the quarter, topping the consensus estimate of $8.18 by $4.38. The biopharmaceutical company had revenue of $3.41 billion for the quarter, compared to analyst estimates of $3.11 billion. Regeneron Pharmaceuticals had a net margin of 33.81% and a trailing twelve-month return on equity of 20.41%. The business's revenue for the quarter was down 31.1% compared to the same quarter last year. During the same quarter last year, the business earned $23.72 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust US Equity Opportunities ETF (FPX), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Simplify Health Care ETF (PINK), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA) and Invesco Dynamic Biotechnology & Genome ETF (PBE).

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (8.63%), BlackRock Inc. (8.61%), State Street Corp (4.48%), Dodge & Cox (2.18%), Geode Capital Management LLC (2.03%) and Price T Rowe Associates Inc. MD (1.99%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REGN stock can currently be purchased for approximately $738.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $80.74 billion and generates $12.17 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $36.80 on an earnings per share basis.

The company employs 11,851 workers across the globe.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.